Aug 5, 2010
ViroPharma Announces Publication of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Jul 28, 2010
ViroPharma Incorporated Reports Second Quarter 2010 Financial Results
Jul 21, 2010
ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
Jun 21, 2010
ViroPharma Files Prior Approval Supplement (PAS) for Cinryze(TM) (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
Jun 3, 2010
ViroPharma to Participate in Two June Healthcare Investor Conferences
May 17, 2010
ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final OpenLabel Data
May 17, 2010
ViroPharma Introduces New Reconstitution System for Cinryze(TM) (C1 Esterase Inhibitor [Human])
Apr 30, 2010
ViroPharma to Participate in Two May Healthcare Investor Conferences
Apr 28, 2010
ViroPharma Incorporated Reports First Quarter 2010 Financial Results
Apr 27, 2010
ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
Apr 21, 2010
ViroPharma to Release 2010 First Quarter Financial Results on April 28, 2010
Mar 31, 2010
ViroPharma Announces Initiation of Phase 2 Study of Cinryze™ (C1 Esterase Inhibitor [Human]) in Pediatric Patients
Mar 24, 2010
ViroPharma Announces Acceptance of Cinryze™ (C1 Esterase Inhibitor [Human]) Marketing Authorization Application (MAA) by European Medicines Agency (EMA)
Mar 19, 2010
Scientific Data Relating to Cinryze™ (C1 Esterase Inhibitor [Human]) Presented at First International Congress of the Southern European Allergy Society
Mar 19, 2010
ViroPharma Launches 'Ryze Above™', A Personalized Patient Resources Program For Patients With Hereditary Angioedema (HAE)
Mar 16, 2010
ViroPharma To Host Investor Day
Mar 2, 2010
ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
Feb 24, 2010
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
Feb 17, 2010
ViroPharma to Release 2009 Fourth Quarter and Full Year Financial Results on February 24, 2010
Jan 11, 2010
ViroPharma Provides 2010 Cinryze™ (C1 Esterase Inhibitor [Human]) Outlook
Jan 11, 2010
ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze™ (C1 esterase inhibitor [human])
Jan 6, 2010
ViroPharma to Participate in the 28th Annual J.P. Morgan Healthcare Conference
Oct 29, 2009
ViroPharma to Present at Three November Healthcare Conferences
Oct 28, 2009
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Oct 15, 2009
ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009
Sep 15, 2009
ViroPharma to Present at Four Additional Healthcare Conferences
Sep 3, 2009
ViroPharma to Present at Several Upcoming Healthcare Conferences
Aug 6, 2009
ViroPharma Announces Initiation Of NonToxigenic Clostridium Difficile Phase 1 Program
Aug 4, 2009
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Jul 29, 2009
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Jul 14, 2009
ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
Jun 8, 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Jun 4, 2009
ViroPharma Receives Complete Response Letter for Cinryze™ Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Jun 2, 2009
ViroPharma to Present at Two June Healthcare Conferences
May 29, 2009
ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
May 26, 2009
Scientific Data Relating to Cinryze™ Presented at 6th Annual C1 Inhibitor Deficiency Workshop
May 18, 2009
http://phx.corporateir.net/phoenix.zhtml?c=92320&p=irolnewsArticle&ID=1289286&highlight=
May 7, 2009
ViroPharma to Present at Two May Healthcare Conferences
Apr 29, 2009
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
Apr 22, 2009
ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
Mar 24, 2009
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
Mar 18, 2009
ViroPharma Submits Comments on Vancocin® Draft Bioequivalence Guidance
Mar 11, 2009
ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
Mar 4, 2009
ViroPharma to Host Investor 'TeachIn' Educational Symposium on Hereditary Angioedema
Feb 24, 2009
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results